OPTX

Business Context and Reporting Period

Company: Syntec Optics Holdings, Inc. (OPTX)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Syntec Optics is a vertically integrated manufacturer of optics and photonics components and sub-systems, specializing in polymer-based and glass optics. The company serves four primary end markets: Defense, Medical (Biomedical), Consumer, and Communications. Following a reverse capitalization merger with OmniLit Acquisition Corp. in November 2023, the company operates as a public entity on the Nasdaq Capital Market.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased by 3.4% ($1.0 million) to $28.45 million. Decreases in Consumer ($0.6M), Defense ($1.0M), and Medical ($0.4M) segments were partially offset by a $1.0 million increase in the Communications segment.
• Margin Compression: Gross margin contracted significantly from 27% to 20%. Cost of Goods Sold (COGS) increased by 6% ($1.2 million) despite lower revenue, driven primarily by a $1.0 million increase in payroll costs (metrology staffing and direct labor) and higher material/subcontractor expenses.
• Operating Expenses: General and Administrative (G&A) expenses rose 30% ($1.9 million) to $8.28 million. Increases were attributed to higher salaries, stock-based compensation for non-employee directors ($0.45 million), and insurance costs.
• Profitability: The company swung from a net income of $1.98 million in 2023 to a net loss of $2.48 million in 2024.

Guidance, Outlook, Risks, and Unusual Items

Management Commentary and Outlook

Management emphasizes a strategy of vertical integration and inorganic growth through acquisitions to consolidate the fragmented photonics industry. The company is expanding into sensing and communications markets, including a supplier role for a NIST-funded R&D project. No specific quantitative revenue or earnings guidance was provided in the text.

Material Risks and Contingencies

• Debt Covenant Defaults: The company failed to meet minimum fixed charge coverage and maximum leverage ratios for Q2 and Q3 2024. A waiver was obtained in November 2024, reducing credit limits and adjusting interest margins. As of December 31, 2024, the company remained non-compliant but held a waiver letter dated March 21, 2025.
• Customer Concentration: Three customers accounted for 48% of total revenue in 2024 (down from 67% in 2023). Loss of these customers would materially impact operations.
• Liquidity Constraints: Cash on hand was only $0.60 million at year-end, with $3.8 million available on a line of credit. Operating cash flow turned negative ($0.94 million used).
• Internal Control Weaknesses: Management identified nine material weaknesses in internal controls over financial reporting, including lack of segregation of duties, inadequate IT general controls, and deficiencies in revenue cut-off and related party transaction identification.
• Regulatory Status: The company received delinquency alerts from NASDAQ in 2025 for missing 10-K and 10-Q filing deadlines. A recovery plan was subsequently accepted.

Unusual Items

• Non-Recurring Expenses: Adjusted EBITDA excludes approximately $1.23 million in non-recurring items for 2024, including executive transition expenses ($0.38M), professional fees ($0.17M), and technology start-up/molding evaluation costs ($0.48M).
• Stock-Based Compensation: $0.45 million in RSUs were granted to non-employee directors in December 2024, fully vested upon grant.

Investor Verification Checklist

• Debt Covenant Compliance: Verify the status of the loan covenant waivers and the company's ability to meet the modified leverage ratios for 2025.
• Liquidity Runway: Assess the sufficiency of the $0.6M cash balance and $3.8M credit line against the negative operating cash flow trend.
• Internal Control Remediation: Review the progress of remediation plans for the nine identified material weaknesses in internal controls.
• Customer Concentration: Monitor the stability of the top three customers representing 48% of revenue.
• NASDAQ Compliance: Confirm the company has maintained its listing status following the 2025 delinquency alerts and recovery plan submission.
• Adjusted EBITDA Quality: Scrutinize the recurring nature of the "non-recurring" expenses excluded from Adjusted EBITDA, particularly technology start-up and molding evaluation costs.